Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients

Stefanie Sauer, Paola A. Erba, Mario Petrini, Andreas Menrad, Leonardo Giovannoni, Chiara Grana, Burkhard Hirsch, Luciano Zardi, Giovanni Paganelli, Giuliano Mariani, Dario Neri, Horst Dürkop, Hans D. Menssen

Research output: Contribution to journalArticle

Abstract

Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extradomain B of fibronectin (ED-BFN) is a promising target for selective cancer therapies. Using immunohistology with a new epitope retrieval technique for paraffin-embedded tissues, ED-B FN expression was found in biopsies from more than 200 Hodgkin and non-Hodgkin lymphoma patients of nearly all entities, and in patients with myeloproliferative diseases. ED-B FN expression was nearly absent in normal lymph nodes (n = 10) and bone marrow biopsies (n = 9). The extent of vascular ED-B FN expression in lymphoma tissues was positively correlated with grade of malignancy. ED-B FN expression was enhanced in lymph nodes with severe lymphadenopa-thy and in some hyperplastic tonsils. The in vivo accessibility of ED-B FN was confirmed in 3 lymphoma patients, in whom the lymphoma lesions were visualized on scintigra-phy with 131I-labeled L19 small immunopro-tein ( 131I-L19SIP). In 2 relapsed Hodgkin lymphoma patients, 131I-L19SIP radioimmu-notherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies. copyright 2007 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)2265-2274
Number of pages10
JournalBlood
Volume113
Issue number10
DOIs
Publication statusPublished - Mar 5 2009

Fingerprint

Hodgkin Disease
Fibronectins
Tumors
Lymphoma
Protein Isoforms
Tissue
Biopsy
Blood Vessels
Neoplasms
Lymph Nodes
Chemotherapy
Palatine Tonsil
Blood vessels
Hematologic Neoplasms
Paraffin
Non-Hodgkin's Lymphoma
Epitopes
Bone
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients. / Sauer, Stefanie; Erba, Paola A.; Petrini, Mario; Menrad, Andreas; Giovannoni, Leonardo; Grana, Chiara; Hirsch, Burkhard; Zardi, Luciano; Paganelli, Giovanni; Mariani, Giuliano; Neri, Dario; Dürkop, Horst; Menssen, Hans D.

In: Blood, Vol. 113, No. 10, 05.03.2009, p. 2265-2274.

Research output: Contribution to journalArticle

Sauer, S, Erba, PA, Petrini, M, Menrad, A, Giovannoni, L, Grana, C, Hirsch, B, Zardi, L, Paganelli, G, Mariani, G, Neri, D, Dürkop, H & Menssen, HD 2009, 'Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients', Blood, vol. 113, no. 10, pp. 2265-2274. https://doi.org/10.1182/blood-2008-06-160416
Sauer, Stefanie ; Erba, Paola A. ; Petrini, Mario ; Menrad, Andreas ; Giovannoni, Leonardo ; Grana, Chiara ; Hirsch, Burkhard ; Zardi, Luciano ; Paganelli, Giovanni ; Mariani, Giuliano ; Neri, Dario ; Dürkop, Horst ; Menssen, Hans D. / Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients. In: Blood. 2009 ; Vol. 113, No. 10. pp. 2265-2274.
@article{335d0c1e11604ad7b1e4e14c849c5454,
title = "Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients",
abstract = "Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extradomain B of fibronectin (ED-BFN) is a promising target for selective cancer therapies. Using immunohistology with a new epitope retrieval technique for paraffin-embedded tissues, ED-B FN expression was found in biopsies from more than 200 Hodgkin and non-Hodgkin lymphoma patients of nearly all entities, and in patients with myeloproliferative diseases. ED-B FN expression was nearly absent in normal lymph nodes (n = 10) and bone marrow biopsies (n = 9). The extent of vascular ED-B FN expression in lymphoma tissues was positively correlated with grade of malignancy. ED-B FN expression was enhanced in lymph nodes with severe lymphadenopa-thy and in some hyperplastic tonsils. The in vivo accessibility of ED-B FN was confirmed in 3 lymphoma patients, in whom the lymphoma lesions were visualized on scintigra-phy with 131I-labeled L19 small immunopro-tein ( 131I-L19SIP). In 2 relapsed Hodgkin lymphoma patients, 131I-L19SIP radioimmu-notherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies. copyright 2007 by The American Society of Hematology.",
author = "Stefanie Sauer and Erba, {Paola A.} and Mario Petrini and Andreas Menrad and Leonardo Giovannoni and Chiara Grana and Burkhard Hirsch and Luciano Zardi and Giovanni Paganelli and Giuliano Mariani and Dario Neri and Horst D{\"u}rkop and Menssen, {Hans D.}",
year = "2009",
month = "3",
day = "5",
doi = "10.1182/blood-2008-06-160416",
language = "English",
volume = "113",
pages = "2265--2274",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients

AU - Sauer, Stefanie

AU - Erba, Paola A.

AU - Petrini, Mario

AU - Menrad, Andreas

AU - Giovannoni, Leonardo

AU - Grana, Chiara

AU - Hirsch, Burkhard

AU - Zardi, Luciano

AU - Paganelli, Giovanni

AU - Mariani, Giuliano

AU - Neri, Dario

AU - Dürkop, Horst

AU - Menssen, Hans D.

PY - 2009/3/5

Y1 - 2009/3/5

N2 - Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extradomain B of fibronectin (ED-BFN) is a promising target for selective cancer therapies. Using immunohistology with a new epitope retrieval technique for paraffin-embedded tissues, ED-B FN expression was found in biopsies from more than 200 Hodgkin and non-Hodgkin lymphoma patients of nearly all entities, and in patients with myeloproliferative diseases. ED-B FN expression was nearly absent in normal lymph nodes (n = 10) and bone marrow biopsies (n = 9). The extent of vascular ED-B FN expression in lymphoma tissues was positively correlated with grade of malignancy. ED-B FN expression was enhanced in lymph nodes with severe lymphadenopa-thy and in some hyperplastic tonsils. The in vivo accessibility of ED-B FN was confirmed in 3 lymphoma patients, in whom the lymphoma lesions were visualized on scintigra-phy with 131I-labeled L19 small immunopro-tein ( 131I-L19SIP). In 2 relapsed Hodgkin lymphoma patients, 131I-L19SIP radioimmu-notherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies. copyright 2007 by The American Society of Hematology.

AB - Current treatment of hematologic malignancies involves rather unspecific chemotherapy, frequently resulting in severe adverse events. Thus, modern clinical research focuses on compounds able to discriminate malignant from normal tissues. Being expressed in newly formed blood vessels of solid cancers but not in normal mature tissues, the extradomain B of fibronectin (ED-BFN) is a promising target for selective cancer therapies. Using immunohistology with a new epitope retrieval technique for paraffin-embedded tissues, ED-B FN expression was found in biopsies from more than 200 Hodgkin and non-Hodgkin lymphoma patients of nearly all entities, and in patients with myeloproliferative diseases. ED-B FN expression was nearly absent in normal lymph nodes (n = 10) and bone marrow biopsies (n = 9). The extent of vascular ED-B FN expression in lymphoma tissues was positively correlated with grade of malignancy. ED-B FN expression was enhanced in lymph nodes with severe lymphadenopa-thy and in some hyperplastic tonsils. The in vivo accessibility of ED-B FN was confirmed in 3 lymphoma patients, in whom the lymphoma lesions were visualized on scintigra-phy with 131I-labeled L19 small immunopro-tein ( 131I-L19SIP). In 2 relapsed Hodgkin lymphoma patients, 131I-L19SIP radioimmu-notherapy induced a sustained partial response, qualifying ED-B FN as a promising target for antibody-based lymphoma therapies. copyright 2007 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=63849261384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63849261384&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-06-160416

DO - 10.1182/blood-2008-06-160416

M3 - Article

C2 - 19131554

AN - SCOPUS:63849261384

VL - 113

SP - 2265

EP - 2274

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -